Monopar Therapeutics, Inc. (MNPR)
112.65
-1.73
(-1.51%)
USD |
NASDAQ |
Sep 09, 16:00
112.65
0.00 (0.00%)
After-Hours: 16:50
Monopar Therapeutics Net Income (Quarterly) : -5.313M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.313M |
| March 31, 2026 | -3.893M |
| December 31, 2025 | -5.201M |
| September 30, 2025 | -3.438M |
| June 30, 2025 | -2.454M |
| March 31, 2025 | -2.625M |
| December 31, 2024 | -10.93M |
| September 30, 2024 | -1.304M |
| June 30, 2024 | -1.715M |
| March 31, 2024 | -1.641M |
| December 31, 2023 | -1.814M |
| September 30, 2023 | -1.954M |
| June 30, 2023 | -2.20M |
| March 31, 2023 | -2.435M |
| December 31, 2022 | -2.896M |
| September 30, 2022 | -2.400M |
| June 30, 2022 | -2.763M |
| March 31, 2022 | -2.457M |
| December 31, 2021 | -2.681M |
| September 30, 2021 | -2.458M |
| Date | Value |
|---|---|
| June 30, 2021 | -2.080M |
| March 31, 2021 | -1.884M |
| December 31, 2020 | -2.128M |
| September 30, 2020 | -1.639M |
| June 30, 2020 | -1.446M |
| March 31, 2020 | -1.091M |
| December 31, 2019 | -1.207M |
| September 30, 2019 | -0.7361M |
| June 30, 2019 | -0.9057M |
| March 31, 2019 | -1.376M |
| December 31, 2018 | -0.8905M |
| September 30, 2018 | -0.6402M |
| June 30, 2018 | -0.8209M |
| March 31, 2018 | -0.8763M |
| December 31, 2017 | -0.7136M |
| September 30, 2017 | -14.88M |
| June 30, 2017 | -0.5914M |
| March 31, 2017 | -0.3729M |
| December 31, 2016 | -0.3205M |
| September 30, 2016 | -0.1931M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.313M |
| EPS Diluted (Quarterly) | -0.622 |
| Enterprise Value | 633.55M |
| Earnings Yield | -2.08% |
| Normalized Earnings Yield | -2.075 |